Simultaneous Estimation and Validation of Tenofovir Disoproxil Fumarate, Emtricitabine and Efavirenz by RP-HPLC Method in Combined tablet Dosage Form

Author(s): Mehdi Rezaei, Ali Ramazani*, Fahimeh Hokmabadi.

Journal Name: Current Pharmaceutical Analysis

Volume 15 , Issue 6 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Introduction: The purpose of this study is the development and validation of assay test for Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC) and Efavirenz (EFV) in combined tablet dosage form by Reverse Phase (RP) HPLC.

Materials and Methods: The assay method by HPLC was found to be linear in the concentration range of 15-150 µg/mL, 10-100 µg/mL and 30-300 µg/mL for TDF, FTC, and EFV, respectively. Successful separation of combined drugs was achieved by isocratic elution on a Phenomenex® C8 column (250 mm × 4.6 mm, 5µm). The mobile phase was composed of buffer pH: 7.0 ± 0.05 potassium dihydrogen phosphate, acetonitrile and methanol (40:40:20 v/v) at the flow rate of 1 mL/min using UV detection at 262 nm, column oven temperature 25ºC, and injection volume 20 µL.

Results: The analytical results were validated by recovery studies. All the parameters of validation were in the acceptance range. This developed method was successfully applied for simultaneous estimation the amount of TDF, FTC and EFV in the bulk and marketed dosage forms.

Keywords: Tenofovir, Emtricitabine, Efavirenz, RP-HPLC, simultaneous estimation, validation.

[1]
Anandakumar, K.; Abirami, G.; Murugan, S.; Ashok, B. RP-HPLC method for simultaneous estimation of Lamivudine, Tenofovir Disoproxil Fumarate and Efavirenz in tablet formulation. J. Anal. Chem., 2013, 68(9), 815-821.
[2]
Bhavsar, D.S.; Patel, B.N.; Patel, C.N. RP-HPLC method for simultaneous estimation of Tenofovir Disoproxil Fumarate, Lamivudine, and efavirenz in combined tablet dosage form. Pharm. Methods, 2012, 3(2), 73-78.
[3]
Mallikarjuna Rao, N.; Gowri Sankar, D. Development and validation of stability-indicating HPLC method for simultaneous determination of Lamivudine, Tenofovir, and Dolutegravir in bulk and their tablet dosage form. FJPS, 2015, 1(2), 73-77.
[4]
Rao, S.; Kumar, N.; Srilekha, K.; Kumari, A. Stability indicating method for the simultaneous estimation of Tenofovir, Emtricitabine and Efavirenz in pure and pharmaceutical dosage form by RP-HPLC. IJARSE, 2016, 5(5), 188-200.
[5]
Kavitha, K.Y.; Geetha, G.; Hariprasad, R.; Venkatnarayanan, R.; Kaviarasu, M. Development and validation of RP-UPLC analytical method for simultaneous estimation of emtricitabine, rilpivirine, Tenofovir Disoproxil Fumarate and its pharmaceutical dosage forms. IRJP, 2013, 4(1), 150-155.
[6]
Ramaswamy, A.; Dhas, A.S.A.G. Development and validation of analytical method for quantitation of Emtricitabine, Tenofovir, Efavirenz based on HPLC. Arab. J. Chem., 2014, 11(2), 275-281.
[7]
Reddy.Yenumula, B.R. Reddy.Singampalli, M.; Reddy.Challa, B.S. Simultaneous estimation of emtricitabine and Tenofovir Disoproxil Fumarate in tablet dosage form by reverse phase high-performance liquid chromatography. IJAT, 2015, 1(1), 6.
[8]
Devrukhakar, P.S.; Borkar, R.; Shastri, N.; Surendranath, K.V. A Validated stability-indicating RP-HPLC method for the simultaneous determination of tenofovir, emtricitabine, and a efavirenz and statistical approach to determine the effect of variables. ISRN Chromatography, 2013, 2013, 1-8.
[9]
Vanitha, C.; Kumar, P.P.; Rajani, S.V.; Swarnalatha, G.; Sekar, V. Simultaneous estimation of emtricitabine and Tenofovir Disoproxil Fumarate in a tablet dosage form by RP-HPLC method. IJPDT, 2014, 4(4), 279-283.
[10]
Chaitanya, M.; Swathi, K.; Raju, P.N.; Swathi, K. Method development and validation of efavirenz by RP-HPLC method. IJPRHS, 2015, 3(3), 763-768.
[11]
Matthews, C.; Woolf, E.; Mazenko, R.; Haddix-Wiener, H.; Chavez-Eng, C.; Constanzer, M.; Doss, G.; Matuszewski, B. Determination of efavirenz, a selective non-nucleoside reverse transcriptase inhibitor, in human plasma using HPLC with post-column photochemical derivatization and fluorescence detection. J. Pharm. Biomed. Anal., 2002, 28(5), 925-934.
[12]
Pradeep Kumar, S.C.D.; Kushnoor, A. Validation and stability of RP-HPLC method for the determination of efavirenz as bulk drug and in pharmaceutical formulations. Int. J. Pharma Bio Sci., 2011, 2(4), 220-231.
[13]
Sandhya, K.; Reddy, N.N.; Manohar, R.; Rajashekar, P. RP-HPLC method development and validation for simultaneous estimation of Lamivudine, zidovudine and nevirapine in tablet dosage form. Indo Am. J. pharm. res., 2014, 4(4), 2133-2140.
[14]
Sarasa-Nacenta, M.a.; Lopez-Púa, Y.; Lopez-Cortes, L.F.; Mallolas, J.; Gatell, J.M.; Carne, X. Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Biomed. Sci. Appl., 2001, 763(1), 53-59.
[15]
Viana, O.D.S.; Medeiros, F.P.M.; Grangeiro-Júnior, S.; Albuquerque, M.M.; Soares, M.F.L.R.; Soares-Sobrinho, J.L.; Alves, L.D.S.; Rolim, L.A.; Silva, K.E.R.D.; Rolim-Neto, P.J. Development and validation of a HPLC analytical assay method for efavirenz tablets: a medicine for HIV infections. Braz. J. Pharm. Sci., 2011, 47(1), 97-102.
[16]
Purnima, B.V.; Reddy, T.V.B.; Rao, Y.S.; Ramu, G.; Ramachandran, D. Stability indicating RP-UPLC method for assay of emtricitabine and Tenofovir Disoproxil Fumarate in bulk and dosage forms. Am. J. Analyt. Chem., 2015, 6(10), 807-821.
[17]
Psrchnp, V.D.; Rao, A.L. Stability-indicating RP-HPLC method for the simultaneous estimation of efavirenz, tenofovir and emtricitabine in pharmaceutical formulations. IJPP, 2014, 1(1), 1-17.
[18]
White, K.L.; Kulkarni, R.; McColl, D.J.; Rhee, M.S.; Szwarcberg, J.; Cheng, A.K.; Miller, M.D. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients. Antivir. Ther., 2015, 20(3), 317-327.
[19]
Siddiqui, M.R.; AlOthman, Z.A.; Rahman, N. Analytical techniques in pharmaceutical analysis: A review. Arabian. J. Chem., 2017, 1, S1409-S1421.
[20]
AlOthman, Z.A.; Rahman, N.; Siddiqui, M.R. Review on pharmaceutical impurities, stability studies and degradation products. Rev. Adv. Sci. Eng., 2013, 2, 155-166.
[21]
Rahman, N.; Azmi, S.N.H.; Wu, H.F. The importance of impurity analysis in pharmaceutical products: An integrated approach. Accred. Qual. Assur., 2006, 11, 69-74.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 6
Year: 2019
Page: [561 - 567]
Pages: 7
DOI: 10.2174/1573412914666180208152021
Price: $58

Article Metrics

PDF: 51
HTML: 5
EPUB: 1
PRC: 1